IntroductionWhile some triple-negative breast cancer (TNBC) patients now have an additional treatment option in the form of Avastin, unmet need remains high. Similarly, despite the availability of Herceptin and Tykerb there is also considerable pipeline activity in HER-2-positive breast cancer. At the same time, there is uncertainty over the optimal way of using Herceptin and Tykerb in this patient subset.Features and benefitsAnalysis of the hormone receptor-negative breast cancer market based on a survey of 180 specialists, supported by opinion leader interviews Epidemiological forecasts of breast cancer incidence and prevalence for the period 2010'19 in the seven major pharmaceutical markets Segmentation of incident cases by age group, menopausal status, stage of disease and subtype In-depth analysis of treatment patterns and regimens prescribed for TNBC and HER-2-positive breast cancer by line of therapy and disease stage HighlightsHerceptin (trastuzumab; Roche/Chugai) has established a formidable position in the HER-2-positive breast cancer market. At relapse, retreatment with an alternative Herceptin-based regimen is favored over switching to Tykerb (lapatinib; GlaxoSmithKline), reflecting the lack of clinical data showing that switching to Tykerb is beneficial.Avastin (bevacizumab; Roche/Chugai) has captured considerable market share in first-line metastatic TNBC in the US; loss of this indication would therefore have a large impact on sales. Avastin is also vulnerable to competition from new market entrants (e.g. Sanofi Aventis's iniparib), even if it retains its breast cancer indication.The popularity of Xeloda (capecitabine; Roche/Chugai) shows that side-effect profile is an important driver of prescribing behavior in metastatic TNBC beyond the first-line of therapy. It is therefore critical that new market entrants in this setting are well tolerated if they are to achieve extensive uptake.Your key questions answeredValidate new product forecasting based on epidemiology, patient segmentation and treatment rates, and the likely rate of uptake for new products Understand prescribing trends and identify key factors that influence treatment choices in defined breast cancer populations Enhance commercial positioning by increasing understanding of current dynamics within the breast cancer market

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) -
Triple-negative breast cancer offers a significant opportunity to new
market entrants while Herceptin dominates the HER-2-positive
market
Published on November 2010
Report Summary
Introduction
While some triple-negative breast cancer (TNBC) patients now have an additional treatment option in the form of Avastin, unmet need
remains high. Similarly, despite the availability of Herceptin and Tykerb there is also considerable pipeline activity in HER-2-positive
breast cancer. At the same time, there is uncertainty over the optimal way of using Herceptin and Tykerb in this patient subset.
Features and benefits
Analysis of the hormone receptor-negative breast cancer market based on a survey of 180 specialists, supported by opinion leader
interviews
Epidemiological forecasts of breast cancer incidence and prevalence for the period 2010'19 in the seven major pharmaceutical
markets
Segmentation of incident cases by age group, menopausal status, stage of disease and subtype
In-depth analysis of treatment patterns and regimens prescribed for TNBC and HER-2-positive breast cancer by line of therapy and
disease stage
Highlights
Herceptin (trastuzumab; Roche/Chugai) has established a formidable position in the HER-2-positive breast cancer market. At relapse,
retreatment with an alternative Herceptin-based regimen is favored over switching to Tykerb (lapatinib; GlaxoSmithKline), reflecting
the lack of clinical data showing that switching to Tykerb is beneficial.
Avastin (bevacizumab; Roche/Chugai) has captured considerable market share in first-line metastatic TNBC in the US; loss of this
indication would therefore have a large impact on sales. Avastin is also vulnerable to competition from new market entrants (e.g.
Sanofi Aventis's iniparib), even if it retains its breast cancer indication.
The popularity of Xeloda (capecitabine; Roche/Chugai) shows that side-effect profile is an important driver of prescribing behavior in
metastatic TNBC beyond the first-line of therapy. It is therefore critical that new market entrants in this setting are well tolerated if they
are to achieve extensive uptake.
Your key questions answered
Validate new product forecasting based on epidemiology, patient segmentation and treatment rates, and the likely rate of uptake for
new products
Understand prescribing trends and identify key factors that influence treatment choices in defined breast cancer populations
Enhance commercial positioning by increasing understanding of current dynamics within the breast cancer market
Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) - Triple-negative breast cancer offers a significant opportunity to new market entrants while Hercept Page 1/5
in dominates the HER-2-positive market (From Slideshare)

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Table of Content
TABLE OF CONTENTS
Overview 1
Catalyst 1
Summary 1
About Datamonitor Healthcare 3
About the Oncology pharmaceutical analysis team 3
Executive Summary 5
Scope of the analysis 5
Datamonitor insight into the hormone receptor-negative breast cancer market 5
Contributing experts 7
Related reports 7
Upcoming related reports 7
1. Introduction and Scope 10
Coverage of the Stakeholder Insight Survey 10
2. Epidemiology 11
Introduction and background 11
Key points 11
Disease definition and diagnosis criteria 12
Global variation and historical trends 12
Risk factors 15
Epidemiologic forecasting of breast cancer 17
Description of methods 21
Epidemiologic Forecast Results 23
Discussion 30
Conclusions 32
3. Disease overview 33
Introduction 33
Patient segmentation 35
4. Treatment options 39
Introduction 39
5. Treatment Trends: Stage I'III 45
Triple-negative breast cancer 45
HER-2-positive breast cancer 59
6. Treatment Trends: Stage IV and Relapse 80
Triple-negative breast cancer 80
HER-2-positive breast cancer 113
7. Future Treatment 144
Late-phase pipeline products overview 144
Future treatment scenarios 196
BIBLIOGRAPHY 201
Chapter 2. Epidemiology 201
Chapter 3. Disease Overview 207
Chapter 4. Treatment Options 209
Chapter 5. Treatment Trends: Stage I'III Breast Cancer 211
Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) - Triple-negative breast cancer offers a significant opportunity to new market entrants while Hercept Page 2/5
in dominates the HER-2-positive market (From Slideshare)

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Chapter 6. Treatment Trends: Stage IV and Relapsed Breast Cancer 212
Chapter 7. Future Treatment 214
APPENDIX A 219
Abbreviations 219
Physician research methodology 219
Physician sample breakdown 220
Contributing experts 221
APPENDIX B 222
The survey questionnaire 222
Datamonitor consulting 276
Disclaimer 277
Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) - Triple-negative breast cancer offers a significant opportunity to new market entrants while Hercept Page 3/5
in dominates the HER-2-positive market (From Slideshare)

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) - Triple-negative breast cancer offers a signi
ficant opportunity to new market entrants while Herceptin dominates the HER-2-positive market
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 15 200.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) - Triple-negative breast cancer offers a significant opportunity to new market entrants while Hercept Page 4/5
in dominates the HER-2-positive market (From Slideshare)

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) - Triple-negative breast cancer offers a significant opportunity to new market entrants while Hercept Page 5/5
in dominates the HER-2-positive market (From Slideshare)